Disc Medicine, Inc. $IRON Stake Trimmed by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 24.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 149,864 shares of the company’s stock after selling 47,960 shares during the period. Victory Capital Management Inc. owned about 0.43% of Disc Medicine worth $9,903,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine during the third quarter valued at approximately $38,000. Avanza Fonder AB raised its stake in Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after purchasing an additional 585 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after purchasing an additional 206 shares in the last quarter. Bryce Point Capital LLC acquired a new stake in shares of Disc Medicine in the third quarter worth $259,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Disc Medicine by 383.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock valued at $211,000 after buying an additional 3,152 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. BMO Capital Markets lowered their target price on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Cantor Fitzgerald dropped their price objective on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Morgan Stanley set a $75.00 target price on shares of Disc Medicine in a research note on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, January 21st. Finally, Wedbush dropped their target price on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.80.

Insider Transactions at Disc Medicine

In other Disc Medicine news, insider Pamela Stephenson sold 5,531 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the completion of the sale, the insider owned 80,998 shares of the company’s stock, valued at $5,091,534.28. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $203,100.66. Following the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $3,414,806.64. This trade represents a 5.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 252,492 shares of company stock worth $21,701,925. 3.64% of the stock is currently owned by company insiders.

Disc Medicine Trading Down 3.5%

Disc Medicine stock opened at $63.85 on Thursday. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $99.50. The company’s fifty day moving average price is $71.89 and its two-hundred day moving average price is $75.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -10.66 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. On average, analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.